Neurocrine Biosciences, Inc. v. Sandoz Inc. et al
| Neurocrine Biosciences, Inc. |
| Sandoz Inc., Sandoz AG, Sandoz International GmbH, Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. |
| 1:2022cv01124 |
| August 26, 2022 |
| US District Court for the District of Delaware |
| Maryellen Noreika |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 19, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 9
ORAL ORDER RESETTING Teleconference - IT IS HEREBY ORDERED that the 10/24/2022 teleconference is RESET for 11/3/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/19/2022. (dlw)
|
|
Filing 8
SO ORDERED re (7 in 1:22-cv-01124-MN) (62 in 1:21-cv-01042-MN) Stipulation as to Joinder and Dismissal of Certain Parties and Order. Signed by Judge Maryellen Noreika on 10/13/2022. (dlw)
|
| Filing 7 STIPULATION as to Joinder and Dismissal of Certain Parties and [Proposed] Order by Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., Sandoz AG, Sandoz Inc., Sandoz International GmbH. (dlw) |
|
Filing 6
ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 10/24/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/6/2022. (dlw)
|
| Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (lam) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,627 ;8,357,697 ;11,311,532. (lam) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/15/2022. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 10/11/2024. (lam) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) |
| Filing 1 COMPLAINT For Patent Infringement against Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., Sandoz AG, Sandoz Inc., Sandoz International GmbH ( Filing fee $ 402, receipt number ADEDC-3946329.) - filed by Neurocrine Biosciences, Inc. (Attachments: #1 Exhibit A-D, #2 Civil Cover Sheet)(lam) |
| No Summons Issued. (lam) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
